For instance, a meta-analysis of seven studies discovered that GLP-1 RA, compared to a placebo, decreases the risk of all-cause mortality in adults with diabetes and cardiovascular disease.22 Except for the investigational oral Semaglutide, the formulations are currently administered as subcutaneous injections at different dosing intervals. Here, GLP1R is linked to cardiovascular disorder.